Microbix completes $1.3 million private placement

Microbix Biosystems (TSX:MBX) has closed a $1.3 million private placement by issuing 3,714,286 common shares at a price of 35 cents each.  The stock closed at 35 cents last Friday. “We felt it was prudent to strengthen our balance sheet while finalizing our partnering arrangements,” CEO William Gastle said in a statement, adding that proceeds [...]

Microbix signs distributor for Kinlytic

Microbix Biosystems (TSX:MBX) has landed Riso Pharma to distribute its Kinlytic drug in the Middle East, with Riso guaranteeing to purchase no less than 50,000 vials of the treatment for pulmonary embolism over the next three years. Sales are expected to begin in mid-2010.  “While final pricing for our therapy has not yet been established, [...]

Microbix cleared to sell Kinlytic

Health Canada has issued a drug identification number for Kinlytic, formerly known as urokinase, allowing Microbix Biosystems (TSX:MBX) to sell its clot-busting therapy in Canada and markets worldwide. In a statement, Toronto-based Microbix said it will now submit an application to Health Canada for approval of its recently acquired urokinase inventory and targets its release [...]

Microbix hits 52-week high on flu vaccine plant

Shares of Microbix Biosystems (TSX:MBX) touched a 52-week high of 66 cents in early Tuesday trading after the company unveiled a joint venture to provide initial financing to build Asia’s largest flu vaccine production plant in China’s Hunan province. The $200-million plant will have an annual capacity to produce more than 100 million doses of [...]

Microbix at “inflection point” bringing pipeline forward

It was a pretty seamless transition for Mark Cochran last year. His latest gig, running a neurosciences institute in West Virginia for the Rockefellers, had come to an end.  He’d been a director of Microbix Biosystems (TSX: MBX) of Toronto since 1990 and a long-time friend of CEO Bill Gastle.  So, when Mr. Gastle asked [...]